National Research (NASDAQ:NRC) Stock Price Crosses Above 200-Day Moving Average – Should You Sell?

Shares of National Research Corporation (NASDAQ:NRC) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $15.77 and traded as high as $15.92. National Research shares last traded at $14.97, with a volume of 264,927 shares traded.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of National Research from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, National Research currently has an average rating of “Sell”.

National Research Price Performance

The company has a market capitalization of $362.79 million, a PE ratio of 32.02 and a beta of 0.53. The stock’s 50-day moving average is $16.97 and its two-hundred day moving average is $15.78. The company has a current ratio of 0.55, a quick ratio of 0.55 and a debt-to-equity ratio of 5.36.

National Research (NASDAQ:NRC) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $0.16 earnings per share (EPS) for the quarter. National Research had a return on equity of 103.84% and a net margin of 8.44%.The company had revenue of $35.19 million during the quarter.

National Research Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 10th. Stockholders of record on Friday, March 27th will be issued a $0.16 dividend. The ex-dividend date is Friday, March 27th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 4.0%. National Research’s dividend payout ratio is presently 128.00%.

Institutional Investors Weigh In On National Research

Several large investors have recently added to or reduced their stakes in the stock. Significant Wealth Partners LLC grew its stake in National Research by 5.4% in the 3rd quarter. Significant Wealth Partners LLC now owns 15,268 shares of the company’s stock worth $195,000 after acquiring an additional 776 shares in the last quarter. M&T Bank Corp boosted its holdings in shares of National Research by 6.4% in the second quarter. M&T Bank Corp now owns 13,608 shares of the company’s stock valued at $229,000 after purchasing an additional 823 shares during the period. Sei Investments Co. grew its stake in National Research by 1.2% in the third quarter. Sei Investments Co. now owns 76,270 shares of the company’s stock worth $975,000 after purchasing an additional 900 shares in the last quarter. Russell Investments Group Ltd. grew its stake in National Research by 85.6% in the third quarter. Russell Investments Group Ltd. now owns 1,997 shares of the company’s stock worth $26,000 after purchasing an additional 921 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in National Research by 6.3% during the 2nd quarter. Invesco Ltd. now owns 17,368 shares of the company’s stock worth $292,000 after purchasing an additional 1,022 shares during the period. 47.26% of the stock is owned by hedge funds and other institutional investors.

About National Research

National Research Corp (NASDAQ: NRC), also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company’s cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.

Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.